SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (2764)5/14/1999 3:40:00 PM
From: Biomaven  Read Replies (2) | Respond to of 10280
 
To clarify my position as well, I'm also in this for the long term and am holding all my shares.

It's unclear what percentage of the costs of Nori development that J&J have been paying (as is normal, this has been redacted in the 10-K version of the agreement).

If the drug has no problems, then SEPR could co-promote it with someone else, like maybe Glaxo. SEPR can't reasonably expect to effectively market this on its own.

Peter



To: RCMac who wrote (2764)5/14/1999 3:47:00 PM
From: LLCF  Read Replies (1) | Respond to of 10280
 
Does everyone see the 15:18 report:

"Sepracor said it will contiue work on the drug, which is in P3 trails. It will present data at upcoing conferences and is on track for submission to the FDA by end of 2000???????"

Basically a repeat with a twist.

Part of a Bloomberg

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News